IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
-6.53%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$384M
AUM Growth
+$384M
(+7.1%)
Cap. Flow
+$55.4M
Cap. Flow
% of AUM
14.41%
Top 10 Holdings %
Top 10 Hldgs %
35.81%
Holding
89
New
18
Increased
39
Reduced
11
Closed
17
Top Buys
| 1 |
Elevance Health
ELV
|
$9.82M |
| 2 |
CRISPR Therapeutics
CRSP
|
$7.53M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$7.2M |
| 4 |
Guardant Health
GH
|
$6.62M |
| 5 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$6.22M |
Top Sells
| 1 |
McKesson
MCK
|
$13.7M |
| 2 |
Abbott
ABT
|
$9.85M |
| 3 |
Fate Therapeutics
FATE
|
$7.61M |
| 4 |
AbbVie
ABBV
|
$6.77M |
| 5 |
Centene
CNC
|
$6.31M |
Sector Composition
| 1 | Healthcare | 97.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
76
McKesson
MCK
$85.9B
| – | – |
-55,000
| Closed | -$13.7M |
|
77
Masimo
MASI
$7.43B
| – | – |
-10,000
| Closed | -$2.93M |
|
78
Lyell Immunopharma
LYEL
$220M
| – | – |
-140,000
| Closed | -$1.08M |
|
79
Lexicon Pharmaceuticals
LXRX
$392M
| – | – |
-200,000
| Closed | -$788K |
|
80
Labcorp
LH
$22.8B
| – | – |
-20,000
| Closed | -$6.28M |
|
81
GSK
GSK
$79.3B
| – | – |
-100,000
| Closed | -$4.41M |
|
|
82
Fate Therapeutics
FATE
$115M
| – | – |
-130,000
| Closed | -$7.61M |
|
83
Edwards Lifesciences
EW
$47.7B
| – | – |
-45,000
| Closed | -$5.83M |
|
84
BridgeBio Pharma
BBIO
$9.91B
| – | – |
0
| – | – |
|
85
Arrowhead Research
ARWR
$3.84B
| – | – |
-50,000
| Closed | -$3.32M |
|
|
AMRN
86
Amarin Corp
AMRN
$311M
| – | – |
-200,000
| Closed | -$674K |
|
|
87
AbbVie
ABBV
$374B
| – | – |
-50,000
| Closed | -$6.77M |
|
|
88
Abbott
ABT
$230B
| – | – |
-70,000
| Closed | -$9.85M |
|
89
Alnylam Pharmaceuticals
ALNY
$58.6B
| – | – |
-20,000
| Closed | -$3.39M |
|